Identification of Metabolic Biomarkers in Bone Marrow Aspirate for Diagnosis, Prognosis, and Therapeutic Monitoring in Pediatric Langerhans Cell Histiocytosis.

Type 1 diabetes (T1D) and phenylketonuria (PKU) are two distinct metabolic disorders whose co-occurrence presents unique clinical challenges. PKU is a rare inherited metabolic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase, which converts phenylalanine to tyrosine. Lifelong adherence to a strict low-phenylalanine diet is required for patients with PKU to prevent intellectual disability and other serious complications. T1D is an autoimmune condition characterized by the destruction of pancreatic beta cells, leading to absolute insulin deficiency and requiring lifelong insulin therapy. This condition typically develops in childhood or adolescence and affects glucose metabolism, necessitating monitoring of blood sugar levels and carbohydrate intake. Diabetes and PKU co-occurrence is more common than expected, though comprehensive epidemiological data remains limited. A large German study of 377 adult PKU patients found significantly higher rates of diabetes compared to matched controls, with unspecified diabetes mellitus showing a prevalence ratio of 1.7 and type 2 diabetes mellitus demonstrating a prevalence ratio of 1.3 []. This increased prevalence has been replicated in other studies, where diabetes mellitus was identified among the conditions with the highest prevalence ratios (1.6–2.3) in PKU patients compared to controls [, ]. The higher prevalence of diabetes in PKU patients has been attributed to the high carbohydrate intake required by the PKU diet, though researchers note that “there is currently no clear evidence that patients with PKU exhibit a higher risk of developing diabetes and most studies only include children or young adults, which may exclude the development timeline of type 2 diabetes mellitus” []. As the PKU population ages due to improved treatments, adults with PKU are increasingly at risk for developing age-related conditions including diabetes []. In contrast to the documented cases of type 2 diabetes, T1D co-occurring with PKU appears to be much rarer [], with only case reports in the literature [, ]. The clinical management of patients with co-occurring PKU and T1D presents unique challenges that require specialized expertise and careful coordination between multiple therapeutic approaches. The complexity of managing both conditions simultaneously is reflected in research practices, where diabetes is commonly listed as an exclusion criterion in PKU studies, limiting the available evidence base for treating these dual-diagnosis patients. This exclusion practice suggests that researchers recognize the potential confounding effects of diabetes on PKU management and outcomes, but it also negatively impacts on generation of evidence-based guidelines for managing both conditions together.